Sorted By Test Name - Mayo Medical Laboratories

TACIF
84388
Transmembrane Activator and CAML Interactor (TACI) Gene,
Full Gene Analysis
Clinical Information: Transmembrane activator and CAML interactor (TACI) is a member of the
tumor-necrosis factor (TNF)-like receptor family, a group of receptors that regulate both survival and
apoptosis of immune cells.(1) TACI is expressed on the surface of resting B cells and activated T cells,
but not resting T cells. TACI interacts with 2 ligands-BAFF (B-cell activating factor), also known as
BLys (B-lymphocyte stimulator), which belongs to the TNF family, and APRIL (a proliferation-inducing
ligand). The ligands for TACI are expressed on macrophages, monocytes, and dendritic cells.(2) TACI
regulates isotype class-switching of immunoglobulins and also is involved in the antibody response to
T-independent antigens.(3) TACI is encoded by the TACI gene (official symbol, TNFRSF13B). The
human TACI gene locus is located on the short arm of chromosome 17, which is a common target for
mutation and rearrangement.(3) The TACI gene consists of 5 exons spanning approximately 35 kb
(including 1002 bp upstream of the 5' untranslated region [UTR] and 1024 bp downstream of the 3' UTR).
The mRNA length is 1377 bp, encoding for a 294-amino acid protein with a molecular weight of 32.34
kD. In recent studies, 4 mutations (D68X [L69fsX11], C104R, A181E, R202H) have been shown to be
statistically significant in common variable immunodeficiency (CVID) and selective IgA deficiency
(sIgAD) patients when compared to controls.(4) In addition, several other mutations have been reported
but none of these appear to be statistically significant when compared to controls.(4) Two other mutations,
P251L and V220A, are considered to be rare polymorphisms as they are present in both controls and
patients.(4-6) The TACI mutations described so far are nonsense, missense, or frameshift (due to the
insertion of a single extra nucleotide) mutations, all of which can be detected by gene sequencing. No
large deletions or duplications have been reported for this gene at this time. CVID is a complex,
heterogeneous disease with defects in 1 or more of these pathways: B-cell survival; circulating memory B
cells (CD27+), including class-switched (CD27+IgM-IgD-), nonswitched (CD27+IgM+IgD+), and
IgM-memory B cells (CD27+IgM+IgD-); B-cell activation after receptor cross-linking; T-cell signaling;
and cytokine expression. CVID patients have hypogammaglobulinemia with impaired functional antibody
responses among other clinical features. While the molecular basis for most cases of CVID and sIgAD
remain unknown, a fraction of CVID cases (approximately 20%-25%) have been reported to be associated
with mutations in TAC, ICOS, BAFF-R, or CD19. Most cases of CID are sporadic, but at least 10% are
familial with a predominance of autosomal dominant over autosomal recessive inheritance. TACI
mutations account for 8% to 15% of CVID cases depending on the study population and are sporadic in
the majority of cases. The familial TACI mutations can be inherited in either an autosomal dominant or
autosomal recessive fashion. There also appears to be variable penetrance in the familial TACI mutations.
(7) TACI mutations appear to be strongly associated with lymphoproliferative diseases such as
splenomegaly or tonsillar hypertrophy. Autoimmune thyroiditis is observed in 15% of TACI
mutation-positive CVID cases. The incomplete penetrance seen for TACI mutations indicates that a
mutation can be present, but the individual does not develop the disease phenotype. The known TACI
mutations appear, in most cases, to be associated with normal protein expression with aberrant or absent
functional activity. Consequently, the vast majority (approximately 95%) of cases cannot be identified by
the flow cytometry analysis (see #88800 "B-Cell Phenotyping Profile for Immunodeficiency and Immune
Competence Assessment, Blood").(7) In less than 5% of TACI-associated CVID cases, protein expression
on B cells is absent, which can be detected by flow cytometry. Therefore, in the presence of a strong
clinical indication for CVID and potential TACI mutations, such as low to absent IgA levels (in the
absence of anti-IgA), lymphoproliferative disease, autoimmune thyroiditis, or autoimmune cytopenias,
TACI genotyping can determine if mutations are present that could explain the clinical phenotype.
Genotyping can also be used to evaluate clinically symptomatic family members of patients with known
TACI mutations for correlation with clinical phenotype and genetic counseling (#89122 "Transmembrane
Activator and CAML Interactor Gene [TACI], Known Mutation Analysis").
Useful For: Evaluating individuals with: -Common variable immunodeficiency (CVID) -Clinically
symptomatic selective IgA deficiency -Lymphoproliferative disease associated with CVID -Autoimmune
phenotypes with CVID These clinical features may be consistent with possible TACI mutations, and the
genotyping test is especially useful as a follow-up test when flow cytometry is uninformative.
Identification of specific TACI mutations in individuals with abnormal TACI flow cytometry results
(from IABCS/88800 B-Cell Phenotyping Profile for Immunodeficiency and Immune Competence
Assessment, Blood).
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 1778